Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC) and ProQR (PRQR)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cartesian Therapeutics (RNAC – Research Report) and ProQR (PRQR – Research Report) with bullish sentiments.
Light Up your Portfolio with Spark:
- Easily identify stocks' risks and opportunities.
- Discover stocks' market position with detailed competitor analyses.
Cartesian Therapeutics (RNAC)
In a report released today, Uy Ear from Mizuho Securities maintained a Buy rating on Cartesian Therapeutics, with a price target of $40.00. The company’s shares closed last Thursday at $16.61, close to its 52-week low of $11.67.
According to TipRanks.com, Ear is a 3-star analyst with an average return of
Cartesian Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $41.75, representing a 143.7% upside. In a report released today, TD Cowen also maintained a Buy rating on the stock.
See Insiders’ Hot Stocks on TipRanks >>
ProQR (PRQR)
JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on ProQR today and set a price target of $8.00. The company’s shares closed last Thursday at $1.74, close to its 52-week low of $1.61.
According to TipRanks.com, Wolleben is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ProQR with a $9.50 average price target, representing a 424.9% upside. In a report issued on March 7, Citi also upgraded the stock to Buy with a $4.00 price target.
Read More on RNAC:
Questions or Comments about the article? Write to editor@tipranks.com- Buy Rating for Cartesian Therapeutics: Promising Clinical Developments and Strong Financial Position
- Amgen data ‘muddies’ outlook for Cartesian, says Oppenheimer
- Cartesian Therapeutics reports FY24 EPS ($4.49) vs. ($49.76) last year
- Cartesian Therapeutics sees cash runway into mid-2027
- Cartesian Therapeutics announces employment inducement grant
